Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

X Roblin

Showing results (51-60 of 82) with videos related to

Pageof 9
Sort By:
La Revue De Medecine Interne|March 8, 2021
[Rituximab immunomonitoring in autoimmune diseases: a support tool in clinical practice?]M Giraud, P Cathébras, X Roblin, et al.
Journal of Crohn'S & Colitis|April 22, 2015
Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel diseaseX Roblin, H Marotte, M Leclerc, et al.
Alimentary Pharmacology & Therapeutics|June 18, 2011
Appendicectomy as a potential therapy for refractory ulcerative proctitisS Bageacu, O Coatmeur, J P Lemaitre, et al.
BMC Gastroenterology|June 21, 2017
Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literatureC Venturin, S Nancey, P Danion, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 8, 2025
Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUSTM Hupé, A Abdelmoula, T Chateau, et al.
Alimentary Pharmacology & Therapeutics|March 26, 2013
Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experienceD Laharie, J Filippi, X Roblin, et al.
La Revue De Medecine Interne|December 27, 2005
[Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients]X Roblin, E Germain, J M Phelip, et al.
Alimentary Pharmacology & Therapeutics|September 22, 2009
Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice surveyA Oussalah, X Roblin, D Laharie, et al.
Alimentary Pharmacology & Therapeutics|April 2, 2005
6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprineX Roblin, F Serre-Debeauvais, J-M Phelip, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawalS Ben-Horin, Y Chowers, B Ungar, et al.
Pageof 9

Showing results (51-60 of 82) with videos related to

Sort By:
Pageof 9
La Revue De Medecine Interne|March 8, 2021
[Rituximab immunomonitoring in autoimmune diseases: a support tool in clinical practice?]M Giraud, P Cathébras, X Roblin, et al.
Journal of Crohn'S & Colitis|April 22, 2015
Combination of C-reactive protein, infliximab trough levels, and stable but not transient antibodies to infliximab are associated with loss of response to infliximab in inflammatory bowel diseaseX Roblin, H Marotte, M Leclerc, et al.
Alimentary Pharmacology & Therapeutics|June 18, 2011
Appendicectomy as a potential therapy for refractory ulcerative proctitisS Bageacu, O Coatmeur, J P Lemaitre, et al.
BMC Gastroenterology|June 21, 2017
Fetal death in utero and miscarriage in a patient with Crohn's disease under therapy with ustekinumab: case-report and review of the literatureC Venturin, S Nancey, P Danion, et al.
Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver|June 8, 2025
Impact of immediate drug optimization of ustekinumab on medium term targets in Crohn's disease: results from the multicentre retrospective real-life study MUSTM Hupé, A Abdelmoula, T Chateau, et al.
Alimentary Pharmacology & Therapeutics|March 26, 2013
Impact of mucosal healing on long-term outcomes in ulcerative colitis treated with infliximab: a multicenter experienceD Laharie, J Filippi, X Roblin, et al.
La Revue De Medecine Interne|December 27, 2005
[Factors associated with hyperhomocysteinemia in inflammatory bowel disease: prospective study in 81 patients]X Roblin, E Germain, J M Phelip, et al.
Alimentary Pharmacology & Therapeutics|September 22, 2009
Tumour necrosis factor antagonists and inflammatory bowel diseases: a national practice surveyA Oussalah, X Roblin, D Laharie, et al.
Alimentary Pharmacology & Therapeutics|April 2, 2005
6-tioguanine monitoring in steroid-dependent patients with inflammatory bowel diseases receiving azathioprineX Roblin, F Serre-Debeauvais, J-M Phelip, et al.
Alimentary Pharmacology & Therapeutics|June 3, 2015
Undetectable anti-TNF drug levels in patients with long-term remission predict successful drug withdrawalS Ben-Horin, Y Chowers, B Ungar, et al.
Pageof 9